Because patient primary tumors and CRPC contain both AR+ and AR−/lo PCa cells/clones and because ARPIs induce plasticity in PCa cells (by reprogramming AR+ PCa cells into AR−/lo cells), it has become clear that both populations of PCa cells need to be therapeutically targeted [12–14]. Here, AR is linked to posterior cortical atrophy.